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Background
Many patients with severe aortic stenosis and coexisting conditions are not candi-
dates for surgical replacement of the aortic valve. Recently, transcatheter aortic-valve 
implantation (TAVI) has been suggested as a less invasive treatment for high-risk 
patients with aortic stenosis.
Methods
We randomly assigned patients with severe aortic stenosis, whom surgeons considered 
not to be suitable candidates for surgery, to standard therapy (including balloon aortic 
valvuloplasty) or transfemoral transcatheter implantation of a balloon-expandable 
bovine pericardial valve. The primary end point was the rate of death from any cause.
Results
A total of 358 patients with aortic stenosis who were not considered to be suitable can-
didates for surgery underwent randomization at 21 centers (17 in the United States). 
At 1 year, the rate of death from any cause (Kaplan–Meier analysis) was 30.7% with 
TAVI, as compared with 50.7% with standard therapy (hazard ratio with TAVI, 0.55; 
95% confidence interval [CI], 0.40 to 0.74; P<0.001). The rate of the composite end 
point of death from any cause or repeat hospitalization was 42.5% with TAVI as com-
pared with 71.6% with standard therapy (hazard ratio, 0.46; 95% CI, 0.35 to 0.59; 
P<0.001). Among survivors at 1 year, the rate of cardiac symptoms (New York Heart 
Association class III or IV) was lower among patients who had undergone TAVI than 
among those who had received standard therapy (25.2% vs. 58.0%, P<0.001). At 30 days, 
TAVI, as compared with standard therapy, was associated with a higher incidence of 
major strokes (5.0% vs. 1.1%, P = 0.06) and major vascular complications (16.2% vs. 
1.1%, P<0.001). In the year after TAVI, there was no deterioration in the functioning 
of the bioprosthetic valve, as assessed by evidence of stenosis or regurgitation on an 
echocardiogram.
Conclusions
In patients with severe aortic stenosis who were not suitable candidates for surgery, 
TAVI, as compared with standard therapy, significantly reduced the rates of death from 
any cause, the composite end point of death from any cause or repeat hospitalization, 
and cardiac symptoms, despite the higher incidence of major strokes and major vascular 
events. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.)
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A ortic stenosis is an insidious disease with a long latency period1 followed by rapid progression after the appearance 
of symptoms,2-5 resulting in a high rate of death 
(approximately 50% in the first 2 years after symp-
toms appear) among untreated patients.1,6-8 Sur-
gical replacement of the aortic valve reduces symp-
toms and improves survival in patients with aortic 
stenosis,9-11 and in the absence of serious coexist-
ing conditions, the procedure is associated with 
low operative mortality.12,13 However, in clinical 
practice, at least 30% of patients with severe symp-
tomatic aortic stenosis do not undergo surgery 
for replacement of the aortic valve, owing to ad-
vanced age, left ventricular dysfunction, or the 
presence of multiple coexisting conditions.14-17 For 
these patients, who are at high surgical risk,18,19 
a less invasive treatment may be a worthwhile al-
ternative.
Transcatheter aortic-valve implantation (TAVI) 
is a new procedure, in which a bioprosthetic valve 
is inserted through a catheter and implanted 
within the diseased native aortic valve. Since 2002, 
when the procedure was first performed,20,21 there 
has been rapid growth in its use throughout the 
world for the treatment of severe aortic stenosis in 
patients who are at high surgical risk.22-32 The 
most recent clinical studies showed that the rate of 
death from any cause at 1 year among patients 
treated with TAVI was approximately 25%.27-29,31 
Thus far, all the studies of TAVI have been obser-
vational registry studies, without standardization 
of end-point definitions33,34 (and unpublished data) 
and without control populations. There is a paucity 
of rigorous, evidence-based clinical data to sub-
stantiate the incremental benefits of TAVI as com-
pared with current standard therapies.
The Placement of Aortic Transcatheter Valves 
(PARTNER) trial was a multicenter, randomized 
clinical trial comparing TAVI with standard ther-
apy in high-risk patients with severe aortic steno-
sis, including a prespecified cohort of patients who 
were not considered to be suitable candidates for 
surgery. In this article, we report the outcomes 
with TAVI as compared with standard therapy 
among the patients in the PARTNER trial who 
were not suitable candidates for surgery.
Me thods
Patient Selection
We enrolled in the PARTNER trial patients with 
severe aortic stenosis and cardiac symptoms for 
whom conventional surgery to replace the aortic 
valve was associated with high risk. Severe aortic 
stenosis was defined as an aortic-valve area of less 
than 0.8 cm2, a mean aortic-valve gradient of 
40 mm Hg or more, or a peak aortic-jet velocity 
of 4.0 m per second or more. All the patients had 
New York Heart Association (NYHA) class II, III, 
or IV symptoms. Patients were divided into two 
cohorts: those who were considered to be candi-
dates for surgery despite the fact that they were 
at high surgical risk, as defined by a Society of 
Thoracic Surgeons (STS) risk score of 10% or 
higher35 (on a scale of 0% to 100%, with higher 
scores indicating greater surgical risk) or by the 
presence of coexisting conditions that would be 
associated with a predicted risk of death by 30 
days after surgery of 15% or higher, and those 
who were not considered to be suitable candi-
dates for surgery because they had coexisting 
conditions that would be associated with a pre-
dicted probability of 50% or more of either death 
by 30 days after surgery or a serious irreversible 
condition. At least two surgeon investigators had 
to agree that the patient was not a suitable can-
didate for surgery. In this article, we report the 
results for the patients with aortic stenosis who 
were not considered to be suitable candidates 
for surgery. The randomized trial involving pa-
tients at high surgical risk who were neverthe-
less considered to be candidates for surgery 
(also NCT00530894) is ongoing.
Pertinent exclusion criteria were a bicuspid or 
noncalcified aortic valve, acute myocardial infarc-
tion, substantial coronary artery disease requir-
ing revascularization, a left ventricular ejection 
fraction of less than 20%, a diameter of the aortic 
annulus of less than 18 mm or more than 25 mm, 
severe (>3+) mitral or aortic regurgitation, a tran-
sient ischemic attack or stroke within the previ-
ous 6 months, and severe renal insufficiency. The 
complete list of inclusion and exclusion criteria 
is provided in Table 1 in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org.
After investigators screened the patients for 
eligibility, Web-based conference calls were con-
ducted by the executive committee to further re-
view and approve the selection of all patients be-
fore randomization. Of the 3105 patients with 
aortic stenosis who were screened by the investi-
gators and the executive committee, approximately 
12% ultimately underwent randomization as part 
of the PARTNER trial and were assigned to the 
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cohort of patients who were not considered to be 
suitable candidates for surgery.
Study Device and Procedure
The Edwards SAPIEN heart-valve system (Edwards 
Lifesciences) consists of a trileaflet bovine peri-
cardial valve and a balloon-expandable, stainless-
steel support frame. The heart valve is shown in 
Figure 1 in the Supplementary Appendix. The TAVI 
procedure was performed in a sterile environment 
(catheterization laboratory or operating room), 
with the patient under general anesthesia; the 
procedure was performed with the use of trans-
esophageal echocardiography. A standard balloon 
aortic valvuloplasty was performed, followed by 
transfemoral insertion of either a 22- or 24-French 
sheath, depending on the selected size of the valve 
(23 mm or 26 mm). The bioprosthetic heart valve, 
crimped onto a balloon catheter, was advanced 
across the native aortic valve. During rapid right 
ventricular pacing, balloon inflation of the crimped 
heart valve and support frame simultaneously de-
ployed the bioprosthetic valve and expanded the 
frame, which was secured to the underlying aor-
tic-valve annulus and leaflets (see videos 1 and 2, 
available at NEJM.org). Adjunctive pharmacologic 
therapy included heparin during the procedure and 
dual antiplatelet therapy (aspirin and clopidogrel) 
for 6 months after the procedure.
Study Design and Oversight
The PARTNER study incorporated two parallel 
prospective, multicenter, randomized, active-treat-
ment–controlled clinical trials. The overall study 
design is shown in Figure 2 in the Supplemen-
tary Appendix. Patients were randomly assigned 
with the use of a computer-generated scheme, 
blocked separately at each participating site and 
for each of the trial cohorts. The PARTNER study 
was approved by the institutional review board at 
each participating site, and all patients provided 
written informed consent.
The trial was designed by the sponsor (Edwards 
Lifesciences) and members of the executive com-
mittee, which included the two academic coprin-
cipal investigators, three interventional cardiolo-
gists, and three cardiac surgeons. The sponsor 
funded the studies and participated in the selec-
tion and management of the sites and the collec-
tion and monitoring of the data. The executive 
committee met in person every 6 to 8 weeks to 
monitor all aspects of the conduct of the trial. The 
coprincipal investigators and the executive com-
mittee had unrestricted access to the data after 
the database was locked, made the decision to 
submit the manuscript for publication, prepared 
all drafts of the manuscript, and attest to the 
integrity of the trial and the completeness and 
accuracy of the reported data, as well as to the 
fidelity of the report to the trial protocol. The 
protocol, including the statistical analysis plan, 
is available at NEJM.org.
Data Management
All serious adverse events were adjudicated by an 
independent clinical events committee. A data and 
safety monitoring board met frequently and had 
access to all study data and treatment assignments 
when requested; the board recommended after 
each meeting that the study be continued with-
out modification. All data were sent for analysis 
to independent consulting biostatisticians. Inde-
pendent core laboratories analyzed all echocar-
diograms and electrocardiograms. The members 
of the committees, the institutions, and the re-
search organizations participating in the PARTNER 
trial are listed in Table 2 in the Supplementary 
Appendix.
Study End Points
The primary end point was the rate of death from 
any cause over the duration of the trial. All pa-
tients were followed for at least 1 year, and cross-
over from the standard-therapy group to the TAVI 
group was not permitted. The coprimary end point 
was the rate of a hierarchical composite of the 
time to death from any cause or the time to the 
first occurrence of repeat hospitalization (after the 
index procedure) due to valve-related or procedure-
related clinical deterioration. This composite end 
point was also reported with the use of more con-
ventional Kaplan–Meier nonhierarchical analyti-
cal methods. Prespecified secondary end points 
included the rate of death from cardiovascular 
causes, NYHA functional class, the rate of repeat 
hospitalization due to valve-related or procedure-
related clinical deterioration, the distance covered 
during a 6-minute walk test,36 valve performance 
(assessed by echocardiography), and the rates of 
myocardial infarction, stroke, acute kidney injury, 
vascular complications, and bleeding. A major 
stroke was defined as a focal or global neurologic 
deficit associated with a score of 2 or higher on 
the modified Rankin scale, which has a range of 
0 to 6, with 0 indicating no symptoms and 6 in-
dicating death. Specific definitions of other im-
Two videos show-
ing deployment  
of the valve and  
animation of the 
TAVI procedure 
are available at 
NEJM.org 
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portant end points are provided in Table 3 in the 
Supplementary Appendix. All patients were fol-
lowed during the index hospitalization; at 30 days, 
6 months, and 1 year; and yearly thereafter.
Statistical Analysis
We estimated that with a sample of 350 patients, 
the study would have at least 85% power to show 
the superiority of TAVI over standard treatment 
with respect to the primary end point, assuming 
that 1-year mortality would be 37.5% in the stan-
dard-treatment group and 25% in the TAVI group. 
In calculating the size of the sample, we also as-
sumed that deaths would follow a constant haz-
ard distribution, that follow-up would continue for 
12 months after the last patient was enrolled, and 
that the rate of loss to follow-up would be 10%.
The analysis of the coprimary end point — the 
hierarchical composite of death or repeat hospi-
talization — was performed with the use of a 
nonparametric method described by Finkelstein 
and Schoenfeld.37 With this method, multiple pair-
wise comparisons are performed for all patient 
pairs, first with respect to the time to death and 
then with respect to the time to repeat hospital-
ization, if necessary. On the basis of a simulation 
with the use of SAS software, we estimated that 
with a total sample of 350 patients, the power for 
this coprimary end point would be more than 
95%. The Hochberg procedure was used to make 
multiple corrections of the primary and coprimary 
end points.
Categorical variables were compared with the 
use of Fisher’s exact test. A generalized linear 
model was used to calculate risk ratios in the sub-
group analysis and to test for interactions. Con-
tinuous variables, which are presented as means 
(±SD), were compared with the use of Student’s 
t-test. All the analyses were performed with data 
from the intention-to-treat population, which in-
cluded all patients who underwent randomization, 
regardless of the treatment actually received. 
Survival curves for time-to-event variables were 
constructed on the basis of all available follow-
up data with the use of Kaplan–Meier estimates 
and were compared with the use of the log-rank 
test. A two-sided alpha level of 0.05 was used for 
all superiority testing. All statistical analyses 
were performed with the use of SAS software, 
version 9.2.
R esult s
Patients and Enrollment
Between May 11, 2007, and March 16, 2009, a total 
of 358 patients with severe aortic stenosis who 
were not suitable candidates for surgery were en-
rolled at 21 sites (17 in the United States) and were 
randomly assigned to TAVI (179 patients) or stan-
dard therapy (179 patients). All the patients were 
followed for at least 1 year (median follow-up pe-
riod, 1.6 years; maximum, 2.8 years). The num-
bers of patients who underwent randomization 
and follow-up are shown in Figure 3 in the Sup-
plementary Appendix.
The baseline characteristics of the patients in 
the two groups were generally well balanced (Ta-
ble 1). The overall patient population was at high 
risk (STS score, 11.6±6.0%). However, there were 
many patients with low STS scores but with co-
existing conditions that contributed to the sur-
geons’ determination that the patient was not a 
suitable candidate for surgery, including an ex-
tensively calcified (porcelain) aorta (15.1%), chest-
wall deformity or deleterious effects of chest-wall 
irradiation (13.1%), oxygen-dependent respiratory 
insufficiency (23.5%), and frailty, as determined 
by the surgeons according to prespecified crite-
ria (23.1%).
Procedural Outcomes
Of the 179 patients assigned to TAVI, 6 (3.4%) 
did not receive a transcatheter heart valve (2 pa-
tients died before the scheduled implantation, 
transfemoral access was unsuccessful in 2 patients, 
and the intraprocedural annulus measurement 
was too large in 2 patients). After randomization, 
the median time to TAVI was 6 days (interquartile 
range, 3 to 11). During the TAVI procedure or in 
the first 24 hours after the procedure, 2 patients 
(1.1%) died, 3 (1.7%) had major strokes, 1 (0.6%) 
had a valve embolization, and 2 (1.1%) underwent 
multiple (≥2) valve implantations; no patient un-
derwent urgent cardiac surgery to manage com-
plications. In the first 30 days after the proce-
dure, 11 of the 173 patients who underwent TAVI 
(6.4%) died.
Of the 179 patients assigned to standard thera-
py, balloon aortic valvuloplasty was performed in 
114 patients (63.7%) during the 30 days after 
randomization and in an additional 36 patients 
The New England Journal of Medicine 
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Table 1. Baseline Characteristics of the Patients and Echocardiographic Findings.*
Characteristic
TAVI
(N = 179)
Standard Therapy
(N = 179) P Value
Age — yr 83.1±8.6 83.2±8.3 0.95
Male sex — no. (%) 82 (45.8) 84 (46.9) 0.92
STS score† 11.2±5.8 12.1±6.1 0.14
Logistic EuroSCORE‡ 26.4±17.2 30.4±19.1 0.04
NYHA class — no. (%) 0.68
II 14 (7.8) 11 (6.1)
III or IV 165 (92.2) 168 (93.9)
Coronary artery disease — no. (%) 121 (67.6) 133 (74.3) 0.20
Previous myocardial infarction — no./total no. (%) 33/177 (18.6) 47/178 (26.4) 0.10
Previous intervention — no./total no. (%)
CABG 58/155 (37.4) 73/160 (45.6) 0.17
PCI 47/154 (30.5) 39/157 (24.8) 0.31
Balloon aortic valvuloplasty 25/154 (16.2) 39/160 (24.4) 0.09
Cerebral vascular disease — no./total no. (%) 48/175 (27.4) 46/167 (27.5) 1.00
Peripheral vascular disease — no./total no. (%) 54/178 (30.3) 45/179 (25.1) 0.29
COPD — no. (%)
Any 74 (41.3) 94 (52.5) 0.04
Oxygen-dependent 38 (21.2) 46 (25.7) 0.38
Creatinine >2 mg/dl (177 μmol/liter) — no./total no. (%) 10/178 (5.6) 17/178 (9.6) 0.23
Atrial fibrillation — no./total no. (%) 28/85 (32.9) 39/80 (48.8) 0.04
Permanent pacemaker — no./total no. (%)  35/153 (22.9)  31/159 (19.5) 0.49
Pulmonary hypertension — no./total no. (%)  50/118 (42.4)  53/121 (43.8) 0.90
Frailty — no./total no. (%)§  21/116 (18.1)  33/118 (28.0) 0.09
Extensively calcified aorta — no. (%) 34 (19.0) 20 (11.2) 0.05
Deleterious effects of chest-wall irradiation — no. (%) 16 (8.9) 15 (8.4) 1.00
Chest-wall deformity — no. (%) 15 (8.4) 9 (5.0) 0.29
Liver disease — no./total no. (%)  6/177 (3.4)  6/178 (3.4) 1.00
Echocardiographic findings
Aortic-valve area — cm2 0.6±0.2 0.6±0.2 0.97
Mean aortic-valve gradient — mm Hg 44.5±15.7 43.0±15.3 0.39
Mean LVEF — % 53.9±13.1 51.1±14.3 0.06
Moderate or severe mitral regurgitation — no./total no. (%)¶  38/171 (22.2)  38/165 (23.0) 0.90
* Plus–minus values are means ±SD. CABG denotes coronary-artery bypass grafting, COPD chronic obstructive pulmonary disease, LVEF left 
ventricular ejection fraction, NYHA New York Heart Associa tion, PCI percutaneous coronary intervention, and TAVI transcatheter aortic-valve 
implantation.
† The Society of Thoracic Surgeons (STS) score measures patient risk at the time of cardiovascular surgery on a scale that ranges from 0% to 
100%, with higher numbers indicating greater risk. An STS score higher than 10% indicates very high surgical risk.
‡ The logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE), which measures patient risk at the time of cardiovascular 
surgery, is calculated with the use of a logistic-regression equation. Scores range from 0% to 100%, with higher scores indicating greater 
risk. A logistic EuroSCORE higher than 20% indicates very high surgical risk.
§ Frailty was determined by the surgeons according to prespecified criteria.
¶ Moderate or severe mitral regurgitation was defined as regurgitation of grade 3+ or higher.
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(20.1%) more than 30 days after randomization. 
Despite the fact that all the patients in this cohort 
of the PARTNER study were determined not to be 
suitable candidates for surgery, 12 of the patients 
who were assigned to standard therapy (6.7%) 
underwent aortic-valve replacement, 5 (2.8%) un-
derwent placement of a conduit from the left ven-
tricular apex to the descending aorta plus aortic-
valve replacement, and 4 (2.2%) underwent TAVI 
at a nonparticipating site outside the United States. 
The 1-year rates of death among patients in the 
standard-therapy group who underwent aortic-
valve replacement, conduit plus aortic-valve re-
placement, or TAVI at a nonparticipating site out-
side the United States were 33%, 80%, and 0%, 
respectively.
Rates of Death, Repeat Hospitalization,  
and Stroke
At 30 days after randomization, the rate of death 
from any cause was 5.0% in the TAVI group as 
compared with 2.8% in the standard-therapy group 
(P = 0.41) (Table 2). At the 1-year follow-up, the rate 
of death from any cause (the primary end point), 
as calculated with the use of a Kaplan–Meier analy-
sis, was 30.7% in the TAVI group, as compared 
with 50.7% in the standard-therapy group (haz-
ard ratio, 0.55; 95% confidence interval [CI], 0.40 
to 0.74; P<0.001) (Fig. 1A). The rate of death from 
cardiovascular causes at 1 year (Kaplan–Meier 
analysis) was also lower in the TAVI group than 
in the standard-therapy group (20.5% vs. 44.6%; 
hazard ratio, 0.39; 95% CI, 0.27 to 0.56; P<0.001) 
(Fig. 1B). The specific cardiovascular and non-
cardiovascular causes of death are shown in Ta-
ble 4 in the Supplementary Appendix.
The superiority of TAVI with respect to the 
coprimary end point (the rate of the hierarchical 
composite of death from any cause or repeat hos-
pitalization) was confirmed by the Finkelstein–
Schoenfeld analysis (P<0.001). In addition, the rate 
of the nonhierarchical composite of death from 
any cause or repeat hospitalization at the 1-year 
follow-up (Kaplan–Meier analysis) was 42.5% with 
TAVI as compared with 71.6% with standard 
therapy (hazard ratio, 0.46; 95% CI, 0.35 to 0.59; 
P<0.001) (Fig. 1C).
Major strokes were observed more frequently 
in the TAVI group than in the standard-therapy 
group at 30 days (5.0% vs. 1.1%, P = 0.06) and at 
1 year (7.8% vs. 3.9%, P = 0.18). However, the rate 
of the composite of major stroke or death from 
any cause (Kaplan–Meier analysis) was still sig-
nificantly lower in the TAVI group than in the 
standard-therapy group (33.0% vs. 51.3% at 1 year; 
hazard ratio, 0.58; 95% CI, 0.43 to 0.78; P<0.001) 
(Fig. 1D). A more detailed analysis of the neuro-
logic events is shown in Table 5 in the Supplemen-
tary Appendix.
Subgroup analyses with interaction testing were 
performed to determine whether the reduction in 
the primary end point (the rate of death from any 
cause) after TAVI was consistent across 10 im-
portant subgroups (Fig. 2). No significant inter-
actions were observed.
Other Clinical Outcomes
The frequencies of other important clinical events 
at 30 days and at 1 year are shown in Table 2. 
Major vascular complications and major bleeding 
events were more frequent in the TAVI group 
than in the standard-therapy group. At 30 days, 
6 months, and 1 year, symptoms were signifi-
cantly reduced in the TAVI group (P<0.001 for all 
three comparisons) (Fig. 3). At 1 year, 74.8% of 
the surviving patients who had undergone TAVI, 
as compared with 42.0% of the surviving patients 
who had received standard therapy, were asymp-
tomatic or had mild symptoms (NYHA class I or II) 
(P<0.001). The 6-minute walk test could be per-
formed in only a subgroup of patients, owing to 
the presence of coexisting conditions in many of 
the patients. At 1 year, a paired analysis of the dis-
tance covered during a 6-minute walk test showed 
that there was significant improvement after TAVI 
(P = 0.002) and no change after standard therapy 
(P = 0.67).
Echocardiographic Findings
Echocardiographic findings are shown in Table 6 
in the Supplementary Appendix. Among patients 
who underwent TAVI, the mean aortic-valve area 
increased from 0.6±0.2 cm2 at baseline to 1.5±0.5 
cm2 at 30 days (P<0.001), and the mean aortic-
valve gradient decreased from 44.5±15.7 mm Hg 
to 11.1±6.9 mm Hg (P<0.001). At the 1-year fol-
low-up assessment, the improvement in aortic-
valve area and mean gradient was maintained.
Moderate or severe paravalvular aortic regur-
gitation was present in 11.8% of the patients in 
the TAVI group at 30 days and in 10.5% at 1 year. 
There were no substantial changes (i.e., changes 
of more than one grade) in paravalvular aortic re-
gurgitation in the TAVI group during the 1-year 
follow-up period. The incidence of moderate or 
severe transvalvular aortic regurgitation was 1.3% 
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Table 2. Clinical Outcomes at 30 Days and 1 Year.*
Outcome 30 Days 1 Year
TAVI 
(N = 179)
Standard 
Therapy
(N = 179) P Value†
TAVI 
(N = 179)
Standard 
Therapy
(N = 179) P Value†
no. of patients (%) no. of patients (%)
Death
From any cause 9 (5.0) 5 (2.8) 0.41 55 (30.7) 89 (49.7) <0.001
From cardiovascular cause‡ 8 (4.5) 3 (1.7) 0.22 35 (19.6) 75 (41.9) <0.001
Repeat hospitalization§ 10 (5.6) 18 (10.1) 0.17 40 (22.3) 79 (44.1) <0.001
Death from any cause or repeat hospitalization§ 19 (10.6) 22 (12.3) 0.74 76 (42.5) 126 (70.4) <0.001
Stroke or TIA
All 12 (6.7) 3 (1.7) 0.03 19 (10.6) 8 (4.5) 0.04
TIA 0 0 — 1 (0.6) 0 1.00
Stroke
Minor 3 (1.7) 1 (0.6) 0.62 4 (2.2) 1 (0.6) 0.37
Major 9 (5.0) 2 (1.1) 0.06 14 (7.8) 7 (3.9) 0.18
Death from any cause or major stroke 15 (8.4) 7 (3.9) 0.12 59 (33.0) 90 (50.3) 0.001
Myocardial infarction
All 0 0 — 1 (0.6) 1 (0.6) 1.00
Periprocedural 0 0 — 0 0 —
Vascular complications
All 55 (30.7) 9 (5.0) <0.001 58 (32.4) 13 (7.3) <0.001
Major 29 (16.2) 2 (1.1) <0.001 30 (16.8) 4 (2.2) <0.001
Acute kidney injury
Creatinine >3 mg/dl (265 μmol/liter)¶ 0 1 (0.6) 1.00 2 (1.1) 5 (2.8) 0.45
Renal-replacement therapy‖ 2 (1.1) 3 (1.7) 1.00 3 (1.7) 6 (3.4) 0.50
Major bleeding 30 (16.8) 7 (3.9) <0.001 40 (22.3) 20 (11.2) 0.007
Cardiac reintervention
Balloon aortic valvuloplasty 1 (0.6)** 2 (1.1) 1.00 1 (0.6) 66 (36.9)†† <0.001
Repeat TAVI‡‡ 3 (1.7) NA — 3 (1.7) NA —
Aortic-valve replacement 0 3 (1.7) 0.25 2 (1.1)** 17 (9.5) <0.001
Endocarditis 0 0 — 2 (1.1) 1 (0.6) 0.31
New atrial fibrillation 1 (0.6) 2 (1.1) 1.00 1 (0.6) 3 (1.7) 0.62
New pacemaker 6 (3.4) 9 (5.0) 0.60 8 (4.5) 14 (7.8) 0.27
* NA denotes not applicable, TAVI transcatheter aortic-valve implantation, and TIA transient ischemic attack.
† P values are for between-group comparisons of the frequency of the event at each time point.
‡ Deaths from unknown causes were assumed to be deaths from cardiovascular causes.
§ Repeat hospitalizations were included if they were due to aortic stenosis or complications of the valve procedure (e.g., TAVI).
¶ Patients who received renal-replacement therapy were not included.
‖ Patients who received renal-replacement therapy after randomization were included.
** One patient in the TAVI group did not receive TAVI (because of failed access) and subsequently underwent balloon aortic valvuloplasty, 
followed by aortic-valve replacement.
†† A total of 30 patients underwent a repeat balloon aortic valvuloplasty after the index balloon aortic valvuloplasty procedure that had been 
performed in the first 30 days after randomization, and 36 patients underwent a first balloon aortic valvuloplasty more than 30 days after 
randomization.
‡‡ Three patients underwent a repeat TAVI within 24 hours after the index TAVI procedure; four patients in the standard-therapy group who 
underwent TAVI at a nonparticipating site outside the United States are not included here.
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at 30 days and 4.2% at 1 year among patients in 
the TAVI group, as compared with 16.9% and 
15.2%, respectively, among patients in the stan-
dard-therapy group. Three patients in the TAVI 
group (1.7%) had to undergo an additional pro-
cedure (repeat TAVI) to treat clinically significant 
aortic regurgitation (paravalvular in two patients 
and transvalvular in one).
Discussion
The main results from the PARTNER trial in the 
cohort of patients with aortic stenosis who were 
not suitable candidates for surgery can be sum-
marized as follows. First, standard medical ther-
apy (including balloon aortic valvuloplasty, which 
was performed in 83.8% of the patients in the 
standard-therapy group) did not alter the natural 
history of severe aortic stenosis; at the end of 
1 year, the rate of death from any cause was 50.7%, 
and the rate of death from cardiovascular causes 
was 44.6%. Second, transfemoral TAVI was supe-
rior to standard therapy, markedly reducing the rate 
of death from any cause (the primary end point), 
the rate of death from cardiovascular causes, and 
the rate of repeat hospitalization. In the first 
year, only five patients needed to be treated with 
TAVI to prevent one death, and only three pa-
tients needed to be treated to prevent either a death 
or repeat hospitalization. Third, the rate of death 
at 30 days among patients who underwent TAVI 
(5.0% in the intention-to-treat population, and 
6.4% among patients who underwent TAVI) did 
not differ significantly from that among patients 
who received standard therapy in this cohort of 
patients who were not suitable candidates for sur-
gery, despite the use of early-generation systems 
for TAVI and minimal operator experience with 
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Figure 1. Time-to-Event Curves for the Primary End Point and Other Selected End Points.
Event rates were calculated with the use of Kaplan–Meier methods and compared with the use of the log-rank test. Deaths from unknown 
causes were assumed to be deaths from cardiovascular causes.
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the TAVI procedure before the trial was initiated. 
Fourth, TAVI was also associated with a signifi-
cant reduction in symptoms, as assessed with the 
use of the NYHA classification system and the 
results of a 6-minute walk test. Fifth, there were 
more neurologic events (including all strokes and 
major strokes), major vascular complications, and 
major bleeding events in the TAVI group than in 
the standard-therapy group. Sixth, echocardio-
graphic findings after TAVI indicated that the 
hemodynamic performance of the bioprosthetic 
valve was excellent and that there was no evidence 
of deterioration in the first year. TAVI was ac-
companied by the frequent occurrence of paraval-
vular regurgitation, which was usually mild, re-
mained stable during the 1-year follow-up period, 
and rarely required further treatment for worsen-
ing symptoms.
The early clinical outcomes (at ≤30 days) after 
transfemoral TAVI were similar to those seen in 
other recent studies of the same balloon-expand-
able bovine pericardial heart valve.28,29,31,32 Un-
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Figure 2. Subgroup Analyses of the Primary End Point of Death from Any Cause.
Relative risks and 95% confidence intervals are shown for the primary end point of death from any cause at 1 year among patients random-
ly assigned to transcatheter aortic-valve implantation (TAVI) or standard therapy. The P value for interaction represents the likelihood  
of an interaction between the variable and the relative treatment effect. The body-mass index is the weight in kilograms divided by the 
square of the height in meters. The Society of Thoracic Surgeons (STS) score measures patient risk at the time of cardiovascular surgery 
on a scale that ranges from 0% to 100%, with higher scores indicating greater risk. Moderate or severe mitral regurgitation was defined 
as regurgitation of grade 3+ or higher. CABG denotes coronary-artery bypass grafting, COPD chronic obstructive pulmonary disease, LV 
left ventricular, NNT number needed to treat, and PCI percutaneous coronary intervention.
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doubtedly, the large femoral access sheaths that 
are required to insert this TAVI system contrib-
uted to the frequent occurrence of vascular com-
plications and bleeding events. Ongoing studies 
are assessing the use of a lower-profile valve and 
support frame, which may reduce vascular com-
plications, allow patients who have smaller ilio-
femoral arteries than did patients in this study 
to undergo this procedure, and facilitate percu-
taneous access and closure.
Strokes remain a troublesome adverse effect 
following TAVI; strokes occur more frequently 
among patients who undergo TAVI than among 
patients who receive standard therapy. Recently, 
diffusion-weighted magnetic resonance imag-
ing studies have shown that there are new per-
fusion deficits in many patients after TAVI, pre-
sumably due to atherothrombotic emboli.38,39 
The combination of smaller, less traumatic TAVI 
systems than the ones currently in use and novel 
cerebral protection devices is being evaluated in 
an effort to reduce the frequency of embolic neu-
rologic events associated with TAVI. Additional 
randomized clinical trials are needed to com-
pare the frequency of procedural strokes after 
TAVI with the frequency after surgical aortic-
valve replacement.
Our study has several limitations. The protocol-
mandated selection criteria excluded important 
patient subgroups, such as patients requiring treat-
ment of coronary stenoses and patients with se-
vere peripheral vascular disease. An assessment 
of the durability and the long-term clinical safety 
and effectiveness of the bioprosthetic valves will 
require more prolonged follow-up of patients who 
participated in the PARTNER trial and in other 
clinical trials of TAVI. Because TAVI was a rela-
tively new procedure in the United States at the 
time the PARTNER trial was conducted, there was 
still a learning curve for most of the surgeons 
and interventional cardiologists who performed 
TAVI in the United States, and this relative inex-
perience was compounded by the use of an earlier-
generation delivery system that was more likely to 
cause complications.
On the basis of a rate of death from any cause 
at 1 year that was 20 percentage points lower with 
TAVI than with standard therapy, balloon-expand-
able TAVI should be the new standard of care for 
patients with aortic stenosis who are not suitable 
candidates for surgery (like the patients enrolled 
in this study). These results cannot be extrapo-
lated to other patients with aortic stenosis. Addi-
tional randomized trials are needed to compare 
TAVI with aortic-valve replacement among high-
risk patients with aortic stenosis for whom surgery 
is a viable option and among low-risk patients with 
aortic stenosis.
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Figure 3. Symptom Status over Time.
Symptom status according to New York Heart Association (NYHA) class is 
shown at baseline and at 30 days, 6 months, and 1 year among patients 
randomly assigned to transcatheter aortic-valve implantation (TAVI) or 
standard therapy (Standard).
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